BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Bednarz-Misa I, Fortuna P, Diakowska D, Jamrozik N, Krzystek-Korpacka M. Distinct Local and Systemic Molecular Signatures in the Esophageal and Gastric Cancers: Possible Therapy Targets and Biomarkers for Gastric Cancer. Int J Mol Sci 2020;21:E4509. [PMID: 32630408 DOI: 10.3390/ijms21124509] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
2 Rana N, Gosain R, Lemini R, Wang C, Gabriel E, Mohammed T, Siromoni B, Mukherjee S. Socio-Demographic Disparities in Gastric Adenocarcinoma: A Population-Based Study. Cancers (Basel) 2020;12:E157. [PMID: 31936436 DOI: 10.3390/cancers12010157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
3 Li F, Li J, Yu J, Pan T, Yu B, Sang Q, Dai W, Hou J, Yan C, Zang M, Zhu Z, Su L, Li YY, Liu B. Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. EBioMedicine 2021;69:103436. [PMID: 34157484 DOI: 10.1016/j.ebiom.2021.103436] [Reference Citation Analysis]
4 Sun L, Zhang Y, Zhang C. Distinct Expression and Prognostic Value of MS4A in Gastric Cancer. Open Med (Wars) 2018;13:178-88. [PMID: 29756054 DOI: 10.1515/med-2018-0028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
5 Li S, Peng L, Tan C, Zeng X, Wan X, Luo X, Yi L, Li J. Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS One 2020;15:e0232240. [PMID: 32379763 DOI: 10.1371/journal.pone.0232240] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang Y, Zhang J, Shen Q, Yin W, Huang H, Liu Y, Ni Q. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett 2018;15:8789-95. [PMID: 29805618 DOI: 10.3892/ol.2018.8365] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
7 Lee J, Yoon HI, Rha SY, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS. Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Clin Transl Oncol 2017;19:1268-75. [DOI: 10.1007/s12094-017-1665-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Li J. Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis. Gastroenterol Res Pract 2020;2020:9512707. [PMID: 32190044 DOI: 10.1155/2020/9512707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
9 Gu F, Liu Y, Liu Y, Cheng S, Yang J, Kang M, Duan W, Liu Y. Distinct functions and prognostic values of RORs in gastric cancer. Open Med (Wars) 2020;15:424-34. [PMID: 33336001 DOI: 10.1515/med-2020-0406] [Reference Citation Analysis]
10 Yang SY, Roh KH, Kim YN, Cho M, Lim SH, Son T, Hyung WJ, Kim HI. Surgical Outcomes After Open, Laparoscopic, and Robotic Gastrectomy for Gastric Cancer. Ann Surg Oncol 2017;24:1770-7. [PMID: 28357674 DOI: 10.1245/s10434-017-5851-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
11 Abozeid M, Rosato A, Sommaggio R. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. Biomed Res Int 2017;2017:5791262. [PMID: 28781967 DOI: 10.1155/2017/5791262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
12 Liu Q, Jiang J, Fu Y, Liu T, Yu Y, Zhang X. MiR-129-5p functions as a tumor suppressor in gastric cancer progression through targeting ADAM9. Biomed Pharmacother. 2018;105:420-427. [PMID: 29879625 DOI: 10.1016/j.biopha.2018.05.105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
13 Choi JH, Lee J, Choi IJ, Kim YW, Ryu KW, Kim J. Genetic Variation in the TAS2R38 Bitter Taste Receptor and Gastric Cancer Risk in Koreans. Sci Rep 2016;6:26904. [PMID: 27245112 DOI: 10.1038/srep26904] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
14 Tan B, Li Y, Di Y, Fan L, Zhao Q, Liu Q, Wang D, Jia N. Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. J Clin Lab Anal 2018;32:e22363. [PMID: 29168576 DOI: 10.1002/jcla.22363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
15 Beeharry MK, Zhang TQ, Liu WT, Gang ZZ. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol 2020;18:51. [PMID: 32151257 DOI: 10.1186/s12957-020-01819-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 Du C, Li DQ, Li N, Chen L, Li SS, Yang Y, Hou MX, Xie MJ, Zheng ZD. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. Sci Rep. 2017;7:42876. [PMID: 28216662 DOI: 10.1038/srep42876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
17 De B, Rhome R, Jairam V, Özbek U, Holcombe RF, Buckstein M, Ang C. Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer 2018;21:889-99. [PMID: 29691758 DOI: 10.1007/s10120-018-0826-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
18 You D, Wang D, Liu P, Chu Y, Zhang X, Ding X, Li X, Mao T, Jing X, Tian Z, Pan Y. MicroRNA-498 inhibits the proliferation, migration and invasion of gastric cancer through targeting BMI-1 and suppressing AKT pathway. Hum Cell 2020;33:366-76. [PMID: 32056164 DOI: 10.1007/s13577-019-00313-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
19 Wang DD, Jin Q, Wang LL, Han SF, Chen YB, Sun GD, Sun SF, Sun SW, Wang T, Liu FJ, Wang P, Shi B. The significance of ENAH in carcinogenesis and prognosis in gastric cancer. Oncotarget 2017;8:72466-79. [PMID: 29069803 DOI: 10.18632/oncotarget.19801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
20 Li W, Liu J. Overexpression of the zinc-α2-glycoprotein accelerates apoptosis and inhibits growth via the mTOR/PTEN signaling pathway in gastric carcinoma cells. Life Sci 2020;240:117117. [PMID: 31790689 DOI: 10.1016/j.lfs.2019.117117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dong X, Su H, Jiang F, Li H, Shi G, Fan L. miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer. Oncol Lett 2018;15:8311-8. [PMID: 29805563 DOI: 10.3892/ol.2018.8421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
22 Pawłowska N, Gornowicz A, Bielawska A, Surażyński A, Szymanowska A, Czarnomysy R, Bielawski K. The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives in human gastric cancer cells. Invest New Drugs 2018;36:970-84. [PMID: 29549610 DOI: 10.1007/s10637-018-0584-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Roh CK, Choi YY, Choi S, Seo WJ, Cho M, Jang E, Son T, Kim HI, Kim H, Hyung WJ, Huh YM, Noh SH, Cheong JH. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Med J 2019;60:132-9. [PMID: 30666834 DOI: 10.3349/ymj.2019.60.2.132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
24 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhou SK, Yang LL, Chen R, Lu Y, Zheng YH. HLA-DQB1*03 genotype and perioperative blood transfusion are not conducive to the prognosis of patients with gastric cancer. J Clin Lab Anal 2018;32:e22443. [PMID: 29667729 DOI: 10.1002/jcla.22443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Tian X, Ju H, Yang W. An ego network analysis approach identified important biomarkers with an association to progression and metastasis of gastric cancer. J Cell Biochem 2019;120:15963-70. [PMID: 31081222 DOI: 10.1002/jcb.28873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
27 Pan J, Zhou H, Zhao X, Ding H, Qin L, Pan Y. Long-term oncological outcomes in robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a meta-analysis. Surg Endosc 2017;31:4244-51. [DOI: 10.1007/s00464-017-5891-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
28 Choi YY, Cho M, Kwon IG, Son T, Kim HI, Choi SH, Cheong JH, Hyung WJ. Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Med J 2019;60:235-42. [PMID: 30799586 DOI: 10.3349/ymj.2019.60.3.235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Choi YY, Noh SH, Cheong JH. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med. 2016;50:1-9. [PMID: 26498010 DOI: 10.4132/jptm.2015.09.10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
30 Kim JH, Kim J, Lee WJ, Seong H, Choi H, Ahn JY, Jeong SJ, Ku NS, Son T, Kim HI, Han SH, Choi JY, Yeom JS, Hyung WJ, Song YG, Noh SH. A High Visceral-To-Subcutaneous Fat Ratio is an Independent Predictor of Surgical Site Infection after Gastrectomy. J Clin Med 2019;8:E494. [PMID: 30979055 DOI: 10.3390/jcm8040494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Liu F, Wang H, Zhang M. Distinct prognostic values and antitumor effects of tumor growth factor β1 and its receptors in gastric cancer. Oncol Lett 2020;20:2621-32. [PMID: 32782580 DOI: 10.3892/ol.2020.11849] [Reference Citation Analysis]
32 Wan L, Tan N, Zhang N, Xie X. Establishment of an immune microenvironment-based prognostic predictive model for gastric cancer. Life Sciences 2020;261:118402. [DOI: 10.1016/j.lfs.2020.118402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]